Search

Your search keyword '"Domingo Pere"' showing total 124 results
Start Over Author "Domingo Pere" Publisher lippincott williams & wilkins
124 results on '"Domingo Pere"'

2. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.

Author

Mocroft, Amanda, Pelchen-Matthews, Annegret, Hoy, Jennifer, Llibre, Josep M., Neesgaard, Bastian, Jaschinski, Nadine, Domingo, Pere, Rasmussen, Line Dahlerup, Gu¨nthard, Huldrych F., Surial, Bernard, Öllinger, Angela, Knappik, Michael, de Wit, Stephane, Wit, Ferdinand, Mussini, Cristina, Vehreschild, Joerg, Monforte, Antonella D'Arminio, Sonnerborg, Anders, Castagna, Antonella, and Anne, Alain Volny

Published
2024
Full Text
View/download PDF

4. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period.

Author

Kowalska, Justyna D., Pelchen-Matthews, Annegret, Ryom, Lene, Losso, Marcelo H., Trofimova, Tatiana, Mitsura, Viktar M., Khromova, Irina, Paduta, Dzmitry, Stephan, Christoph, Domingo, Pere, Bakowska, Elzbieta, Monforte, Antonella d'Arminio, Oestergaard, Lars, Jablonowska, Elzbieta, Kuznetsova, Anastasiia, Moreno, Santiago, Vasylyev, Marta, Pradier, Christian, Battegay, Manuel, and Vandekerckhove, Linos

Published
2021
Full Text
View/download PDF

5. Uptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antivirals

Author

Peters, Lars, Laut, Kamilla, Resnati, Chiara, Del Campo, Santos, Leen, Clifford, Falconer, Karolin, Trofimova, Tatyana, Paduta, Dzmitry, Gatell, Jose, Rauch, Andri, Lacombe, Karine, Domingo, Pere, Chkhartishvili, Nikoloz, Zangerle, Robert, Matulionyte, Raimonda, Mitsura, Viktar, Benfield, Thomas, Zilmer, Kai, Khromova, Irina, Lundgren, Jens, Rockstroh, Jürgen, and Mocroft, Amanda

Subjects
610 Medicine & health
Abstract

BACKGROUND AND AIMS To investigate the uptake of HCV therapy among HIV/HCV coinfected patients in the pan-European EuroSIDA study between 2011-2016. METHODS All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting first IFN-free direct-acting antiviral (DAA) therapy was calculated. Factors associated with starting IFN-free DAA were determined by Poisson regression. RESULTS Among 4308 HCV-RNA+ patients (1255, 970, 663, 633, 787 from South, West, North, Central East and East Europe, respectively) with 11863 person years of follow up (PYFU), 1113 (25.8%) started any HCV therapy. Among patients with ≥F3 fibrosis, >50% in all regions remained untreated. The incidence (per 1000 PYFU, 95% CI) of starting DAA increased from 7.8 (5.9 - 9.8) in 2014 to 135.2 (122.0 - 148.5) in 2015 and 128.9 (113.5 - 144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, females, individuals from Central East or East, genotype 3, antiretroviral therapy naïve and those with detectable HIV-RNA were less likely to start DAA. Older persons, those with HCV-RNA >500.000 IU/ml and those with more advanced liver fibrosis were more likely to start DAA. CONCLUSIONS Uptake of DAA therapy among HIV/HCV coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with ≥F3 fibrosis remained untreated. Women were less likely to start DAA.

Published
2018
Full Text
View/download PDF

6. Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations

Author

Laut, Kamilla Gronborg, Shepherd, Leah, Gottfredsson, Magnus, Sedlacek, Dalibor, Knysz, Brygida, Begovac, Josip, Radoi, Roxana, Schmied, Brigitte, Chkhartishvili, Nikoloz, Florence, Eric, Ristola, Matti, Faetkenheuer, Gerd, Mulcahy, Fiona, Schmid, Patrick, Kuzovatova, Elena, Paduta, Dzmitry, Smidt, Jelena, Domingo, Pere, Szlavik, Janos, Lundgren, Jens, Mocroft, Amanda, Kirk, Ole, Laut, Kamilla Gronborg, Shepherd, Leah, Gottfredsson, Magnus, Sedlacek, Dalibor, Knysz, Brygida, Begovac, Josip, Radoi, Roxana, Schmied, Brigitte, Chkhartishvili, Nikoloz, Florence, Eric, Ristola, Matti, Faetkenheuer, Gerd, Mulcahy, Fiona, Schmid, Patrick, Kuzovatova, Elena, Paduta, Dzmitry, Smidt, Jelena, Domingo, Pere, Szlavik, Janos, Lundgren, Jens, Mocroft, Amanda, and Kirk, Ole

Abstract

Objectives: We assessed differences in antiretroviral treatment (ART) coverage and virological suppression across three HIV key populations, as defined by self-reported HIV transmission category: sex between men, injection drug use (IDU) and heterosexual transmission. Design: A multinational cohort study. Methods: Within the EuroSIDA study, we assessed region-specific percentages of ART coverage among those in care and virological suppression (<500 copies/ml) among those on ART, and analysed differences between transmission categories using logistic regression. Results: Among 12 872 participants followed from 1 July 2014 to 30 June 2016, the percentages of ART-coverage and virological suppression varied between transmission categories, depending on geographical region (global P for interaction: P = 0.0148 for ART-coverage, P = 0.0006 for virological suppression). In Western [adjusted odds ratio (aOR) 1.41 (95% confidence interval 1.14-1.75)] and Northern Europe [aOR 1.68 (95% confidence interval 1.25-2.26)], heterosexuals were more likely to receive ART than MSM, while in Eastern Europe, there was some evidence that infection through IDU [aOR 0.60 (95% confidence interval 0.31-1.14)] or heterosexual contact [aOR 0.58 (95% confidence interval 0.30-1.10)] was associated with lower odds of receiving ART. In terms of virological suppression, people infected through IDU or heterosexual contact in East Central and Eastern Europe were around half as likely as MSM to have a suppressed viral load on ART, while we observed no differences in virological suppression across transmission categories in Western and Northern Europe. Conclusion: In our cohort, patterns of ART-coverage and virological suppression among key populations varied by geographical region, emphasizing the importance of tailoring HIV programmes to the local epidemic. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.

Published
2018

7. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.

Author

Amele, Sarah, Peters, Lars, Rodger, Alison, Lundgren, Jens, Rockstroh, Jurgen, Matulionyte, Raimonda, Leen, Clifford, Jabłonowska, Elzbieta, Østergaard, Lars, Bhagani, Sanjay, Sarcletti, Mario, Clarke, Amanda, Falconer, Karolin, Wandeler, Gilles, Domingo, Pere, Maltez, Fernando, Zaccarelli, Mauro, Chkhartisvili, Nikoloz, Szlavik, Janos, and Stephan, Christoph

Published
2021
Full Text
View/download PDF

10. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.

Author

Peters, Lars, Laut, Kamilla, Resnati, Chiara, Del Campo, Santos, Leen, Clifford, Falconer, Karolin, Trofimova, Tatyana, Paduta, Dzmitry, Gatell, Jose, Rauch, Andri, Lacombe, Karine, Domingo, Pere, Chkhartishvili, Nikoloz, Zangerle, Robert, Matulionyte, Raimonda, Mitsura, Viktar, Benfield, Thomas, Zilmer, Kai, Khromova, Irina, and Lundgren, Jens

Published
2018
Full Text
View/download PDF

12. A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients.

Author

Rodríguez-Galleg, Esther, Gómez, Josep, Pacheco, Yolanda M., Perair, Joaquim, Viladés, Consuelo, Beltrán-Debón, Raúl, Mallo, Roger, López-Dupla, Migue, Veloso, Sergi, Alba, Verónica, Blanco, Julià, Cañ ellas, Nicolau, Rull, Anna, Leal, Manuel, Correig, Xavier, Domingo, Pere, Vidal, Francesc, Rodríguez-Gallego, Esther, Pacheco, Yolanda María, and Peraire, Joaquim

Published
2018
Full Text
View/download PDF

13. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Author

Gatell, José M., Assoumou, Lambert, Moyle, Graeme, Waters, Laura, Johnson, Margaret, Domingo, Pere, Fox, Julie, Martinez, Esteban, Stellbrink, Hans–Jürgen, Guaraldi, Giovanni, Masia, Mar, Gompels, Mark, De Wit, Stephane, Florence, Eric, Esser, Stefan, Raffi, François, Pozniak, Anton L., Stellbrink, Hans- Jürgen, and NEAT022 Study Group*

Published
2017
Full Text
View/download PDF

15. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study

Author

Mugavero, Michael J., May, Margaret, Ribaudo, Heather J., Gulick, Roy M., Riddler, Sharon A., Haubrich, Richard, Napravnik, Sonia, Abgrall, Sophie, Phillips, Andrew, Harris, Ross, Gill, M. John, de Wolf, Frank, Hogg, Robert, Guenthard, Huldrych F., Chene, Genevieve, Monforte, Antonella D'Arminio, Guest, Jodie L., Smith, Colette, Murillas, Javier, Berenguer, Juan, Wyen, Christoph, Domingo, Pere, Kitahata, Mari M., Sterne, Jonathan A. C., Saag, Michael S., Mugavero, Michael J., May, Margaret, Ribaudo, Heather J., Gulick, Roy M., Riddler, Sharon A., Haubrich, Richard, Napravnik, Sonia, Abgrall, Sophie, Phillips, Andrew, Harris, Ross, Gill, M. John, de Wolf, Frank, Hogg, Robert, Guenthard, Huldrych F., Chene, Genevieve, Monforte, Antonella D'Arminio, Guest, Jodie L., Smith, Colette, Murillas, Javier, Berenguer, Juan, Wyen, Christoph, Domingo, Pere, Kitahata, Mari M., Sterne, Jonathan A. C., and Saag, Michael S.

Abstract

Background: The generalizability of antiretroviral therapy (ART) clinical trial efficacy findings to routine care settings is not well studied. We compared the relative effectiveness of initial ART regimens estimated in AIDS Clinical Trial Group (ACTG) randomized controlled trials with that among patients receiving ART at Antiretroviral Therapy Cohort Collaboration (ART-CC) study sites. Methods: Treatment-naive HIV-infected patients initiating identical ART regimens in ACTG trials (A5095 and A5142) and at 15 ART-CC cohort study sites were included. Virological failure (HIV-1 RNA.200 copies/mL) at 24 and 48 weeks, incident AIDS-defining events and mortality were measured according to study design (ART-CC cohort vs. ACTG trial) and stratified by third drug [abacavir (ABC), efavirenz (EFV), and lopinavir/r (LPV/r)]. We used logistic regression to estimate and compare odds ratios (OR) for virological failure between different regimens and study designs, and used Cox models to estimate and compare hazard ratios for AIDS and death. Results: Compared with patients receiving ABC, those receiving EFV had roughly half the odds of 24-week virologic failure (>200 copies/mL) in both ACTG 5095 (OR = 0.53, 95% confidence interval: 0.36 to 0.79) and ART-CC (0.46, 0.37 to 0.57). Virologic superiority of EFV (vs. ABC) seemed comparable in ART-CC and ACTG 5095 (ratio of ORs 0.86, 95% confidence interval: 0.54 to 1.35). Odds ratios for 48-week virologic failure, comparing EFV with LPV/r, were also comparable in ACTG 5142 and ART-CC (ratio of ORs: 0.87, 0.45 to 1.69). Conclusions: Between ART regimen virologic efficacy of third drugs ABC, EFV, and LPV/r observed in the ACTG 5095 and 5142 trials seem generalizable to the routine care setting of ART-CC clinical cohorts.

Published
2011

18. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Author

Miro, Jose M., Manzardo, Christian, Ferrer, Elena, Loncà, Montserrat, Guardo, Alberto C., Podzamczer, Daniel, Domingo, Pere, Curran, Adrian, Clotet, Bonaventura, Cruceta, Anna, Lozano, Francisco, Pérez, Iñaki, Plana, Montserrat, and Gatell, Jose M.

Published
2015
Full Text
View/download PDF

19. A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz.

Author

Domingo, Pere, Gutierrez, Maria del Mar, Gallego-Escuredo, José Miguel, Torres, Ferran, Mateo, Maria Gracia, Villarroya, Joan, Lamarca, Karuna, Domingo, Joan Carles, Vidal, Francesc, Villarroya, Francesc, and Giralt, Marta

Abstract

Conflicting reports on the effects of efavirenz (EFV) and lopinavir/ritonavir (LPV/r) on subcutaneous adipose tissue (SAT) have been described.The aim was to assess the 48-week molecular and clinical effects of LPV/r and EFV, combined with tenofovir/emtricitabine (TDF/FTC), on SAT of HIV-infected, antiretroviral-naive patients.Forty-four adults were started on LPV/r or EFV combined with TDF/FTC. Fasting metabolic tests, HIV RNA, CD4 cell count, and fat measured by dual x-ray absorptiometry scans were obtained at study entry and week 48. Mitochondrial DNA (mtDNA) and transcripts for mtDNA-encoded proteins and genes involved in inflammation, adipocyte differentiation, and metabolism were assessed in paired SAT biopsies.Whole-body fat and limb fat mass increased in the LPV/r and EFV groups. MtDNA and cytochrome oxidase subunit II did not change, and cytochrome b increased significantly in EFV-treated patients. Tumor necrosis factor alpha and monocyte chemotactic protein-1 gene expression did not change in the LPV/r group, but these significantly increased in the EFV group. Interleukin 18 decreased in the LPV/r group, whereas it increased in the EFV group.Starting TDF/FTC plus EFV was associated with an increased expression of genes encoding for inflammatory cytokines in SAT in naive patients. Therapy with TDF/FTC plus LPV/r or EFV was associated with an increase in subcutaneous fat mass. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

20. Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls.

Author

Negredo, Eugènia, Domingo, Pere, Ferrer, Elena, Estrada, Vicente, Curran, Adrià, Navarro, Antonio, Isernia, Valentina, Rosales, Joaquim, Pérez-Álvarez, Núria, Puig, Jordi, Bonjoch, Anna, Echeverría, Patricia, Podzamczer, Daniel, and Clotet, Bonaventura

Abstract

Peak bone mass (PBM) is the amount of bone present at the end of skeletal maturation. It is an important determinant of osteoporotic fracture risk. Data on the PBM in the HIV-infected population are lacking.We performed a multicenter (6 centers in Spain), case-control study to assess PBM using dual-energy x-ray absorptiometry. We studied HIV-infected patients aged 20-30 years and compared them with age- and gender-matched non-HIV-infected controls. We also assessed the predictive factors for a low PBM.We included 307 subjects: 232 HIV-infected patients and 75 non-HIV-infected controls. Bone mineral density was similar in both groups although differences were seen in the total femur T-score (-0.15SD versus +0.50SD, respectively, P = 0.018). The percentage of osteopenia and osteoporosis was higher in the HIV-infected patients (56.5% and 10.7%, respectively) than in the controls (50.7% and 4%, respectively; P = 0.019). Osteoporosis was more frequent in HIV-infected men than in control men and HIV-infected women (12.2% versus 5.5% and 4.8%, P = 0.033). Protease inhibitors and nadir CD4 T-cells were negatively associated with PBM, whereas fat and lean mass were positively associated with PBM.Bone mineral density was similar between HIV-infected patients aged 20-30 years than in age- and gender-matched controls. However, lower femoral T-scores and higher rate of osteopenia and osteoporosis were seen in HIV-infected men. Therapy with protease inhibitors, nadir CD4 counts, and fat and lean mass were predictive factors of PBM. Given that these patients will be living with HIV infection for many years, every effort should be made to modify risk factors. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

23. Reduced Levels of Serum FGF19 and Impaired Expression of Receptors for Endocrine FGFs in Adipose Tissue From HIV-Infected Patients.

Author

Gallego-Escuredo, José M., Domingo, Pere, Gutiérrez, Maria del Mar, Mateo, Maria G., Cabeza, Maria C., Fontanet, Angels, Vidal, Francesc, Domingo, Joan Carles, Giralt, Marta, and Villarroya, Francesc

Abstract

To determine the role of fibroblast growth factor (FGF)-19 and FGF21 and the endocrine FGFs receptor system in the metabolic alterations that manifest in HIV-1-infected patients undergoing highly active antiretroviral treatment (HAART).Serum FGF19 and FGF21 levels were determined in 4 groups of individuals as follows: (1) HIV-1-infected HAART patients with lipodystrophy (n = 38); or (2) without lipodystrophy (n = 34); (3) untreated (naive) HIV-1-infected patients (n = 34); and (4) healthy controls (n = 31). Serum FGF19 levels were correlated with anthropometric, metabolic, HIV-1 infection-related, and HAART-related parameters and with FGF21 levels. The gene expression of FGF receptor 1 and the coreceptor β-Klotho was analyzed in adipose tissue from 10 individuals from each group.Serum FGF19 levels were significantly reduced in all groups of HIV-1-infected patients, whereas FGF21 levels were increased. FGF19 levels were negatively correlated with insulin resistance and insulin levels and positively correlated with high-density lipoprotein cholesterol. FGF19 was inversely correlated with cumulative exposure to nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drugs. The expression of FGF receptor 1 and coreceptor β-Klotho was reduced in adipose tissue from all groups of HIV-infected patients.FGF19 levels are reduced in HIV-1-infected patients, in contrast with FGF21 levels. Impaired expression of the corresponding receptor and coreceptor, which mediate the actions of endocrine FGFs in adipose tissue, suggests a resistance to the metabolic effects of FGF19 and FGF21 in HIV-1-infected patients. Considering the beneficial effects of endocrine FGFs on metabolism, the observed reduction in FGF19 levels and decreased sensitivity to endocrine FGFs in adipose tissue may contribute to metabolic alterations in HIV-1-infected patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

26. Adipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1-Infected Long-Term Nonprogressors.

Author

Vidal, Francesc, Domingo, Pere, Villarroya, Francesc, Giralt, Marta, López-Dupla, Miguel, Gutiérrez, Mar, Gallego-Escuredo, Jose M., Peraire, Joaquim, Viladés, Consuelo, Veloso, Sergi, Mateo, Gracia, Guallar, Jordi P., and Richart, Cristóbal

Abstract

HIV-1 can induce disturbances in adipose tissue in infected subjects through the effects of some of its proteins or inflammation. It is not known whether this also takes place in HIV-1-infected long-term nonprogressors (LTNPs). Our objectives were to determine whether adipocyte differentiation/lipid, inflammatory, and mitochondrial parameters are perturbed in abdominal wall subcutaneous adipose tissue of untreated HIV-1-infected patients LTNPs.Cross-sectional study involving 10 LTNPs, 10 typical progressors (TPs), and 10 uninfected controls (UCs). The parameters assessed were peroxisome proliferator-activated receptor-gamma (PPARγ), lipoprotein lipase, and fatty acid-binding protein 4 mRNA (adipogenic/lipid); tumor necrosis factor-alpha, interleukin 18 (IL-18), β2-MCG, monocyte chemoattractant protein 1, CD1A, and C3 mRNA (inflammation); and cytochrome c oxidase subunit II (COII), COIV, CYCA, nuclear respiratory factor 1, PPARγ coactivator 1α mRNA, and mtDNA content (mitochondrial).Regarding adipogenic/lipid parameters, LTNPs had PPARγ, lipoprotein lipase, and fatty acid-binding protein 4 mRNA significantly decreased compared with UCs (P  0.001 for all comparisons). PPARγ mRNA was significantly greater in LTNP than in TP (P = 0.006). With respect to inflammatory parameters, tumor necrosis factor-alpha, IL-18, and β2-MCG mRNA were significantly higher in LTNPs compared with UCs (P < 0.005 for all comparisons), whereas IL-18 mRNA was greater in TPs compared with LTNPs (P = 0.01). As mitochondrial parameters are concerned, mtDNA was significantly reduced in LTNPs compared with TPs (P = 0.04) and UCs (P = 0.03). COII and COIV were also significantly reduced in LTNPs compared with UCs and TPs.Adipose tissue from untreated LTNPs may have limited but significant derangements in some adipogenic/lipid and may have inflammatory processes at a lower degree than that observed in untreated TPs. LTNPs may have mitochondrial-related alterations in adipose tissue which are greater than that observed in TPs. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

30. Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1 -Infected Adults: 48-Week Results From the ASSERT Study.

Author

Post, Frank A., Moyle, Graeme J., Stelibrink, Hans Jiirgen, Domingo, Pere, Podzamczer, Daniel, Fisher, Martin, Norden, Anthony G., Cavassini, Matthias, Rieger, Armin, Khuong-Josses, Marie-Aude, Branco, Teresa, Pearce, Helen C., Givens, Naomi, Vavro, Cindy, and Lim, Michael L.

Published
2010
Full Text
View/download PDF

31. Bacterial Meningitis in HIV-1 — Infected Patients in the Era of Highly Active Antiretroviral Therapy.

Author

Domingo, Pere, Suarez-Lozano, Ignacio, Torres, Ferran, Pomar, Virginia, Ribera, Esteban, Galindo, MJose, Cosin, Jaime, Garcia-Alcalde, MLuisa, Vidal, Francesc, Lopez-AIdeguer, Jose, Roca, Bernardino, Gonzalez, Juan, Lozano, Fernando, and Garrido, Myriam

Subjects
*HIV-positive persons, *MENINGITIS, *HIGHLY active antiretroviral therapy, *DISEASE incidence, *COHORT analysis
Abstract

The article presents a study on the spontaneous bacterial meningitis (SBM) in HIV-1-infected patients in the highly active antiretroviral therapy. It mentions that 32 episodes of SMB were evaluated among HIV-1-infected patients from the VHI-Applicacion de Control Hospitalario (VACH) Cohort and compared to 267 uninfected patients. It notes the findings including the incidence rate of 62.0 per 100,000 population between 1997 and 2006 in 32 episodes of SMB among HIV-1-infected patients.

Published
2009
Full Text
View/download PDF

32. Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study.

Author

Mallolas, Josep, Podzamczer, Daniel, Milinkovic, Ana, Domingo, Pere, Clotet, Bonaventura, Ribera, Esteve, Gutiérrez, Félix, Knobel, Hernando, Cosin, Jaime, Ferrer, Elena, Arranz, José Alberto, Roca, Victor, Vidal, Francesc, Murillas, Javier, Pich, Judit, Pedrol, Enric, Llibre, Josep M., Dalmau, David, García, Isabel, and Aranda, Miquel

Published
2009
Full Text
View/download PDF

33. Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.

Author

Podzamczer, Daniel, Olmo, Montserrat, Sanz, Jose, Boix, Vicente, Negredo, Eugenia, Knobel, Hernando, Domingo, Pere, Pineda, Juan A., Vilades, Consuelo, Quero, Jose Hernandez, Force, Lluis, Lahoz, Juan Gonzalez, Muñoz, Pepa, Llibre, Josep M., Mariño, Ana, Ortega, Enrique, Dalmau, David, Gatell, Josep M., Antón, Esperanza, and Sola, Julio

Published
2009
Full Text
View/download PDF

37. Effect of Genetic Variants of CCR2 and CCL2 on the Natural History of HIV-1 Infection CCL2-25 1 8GG Is Overrepresented in a Cohort of Spanish HIV-1—Infected Subjects.

Author

Viladés, Consuelo, Broch, Montserrat, Plana, Montserrat, Domingo, Pere, Alonso-Villaverde, Carlos, Pedrol, Enric, Knobel, Hernando, Dalmau, David, Peraire, Joaquim, Gutiérrez, Cristina, Lopez, Anna, Sambeat, Antônia, Olona, Montserrat, Garcia, Felipe, Richart, Cristóbal, GatelI, Josep M., and Vidal, Francesc

Published
2007
Full Text
View/download PDF

44. Failure of Cetirizine to Prevent Nevirapine-Associated Rash A Double-Blind Placebo-Controlled Trial for the GESIDA 26/07 Study.

Author

Knobel, Hernando, Miró, José M., Mahillo, Beatriz, Domingo, Pere, Rivero, Antonio, Ribera, Esteban, Gonzalez, Juan, Sanz, José, Gonzalez, Alicia, Blanco, José Luis, Boix, Vicente, Force, Luis, Llibre, Josep M., Dalmau, David, Arroyo, Juan A., De la Torre, Julián, Rodriguez, Dolors, Montes, Maria Luisa, Arranz, Alberto, and Sarasa, Maria

Published
2004
Full Text
View/download PDF

50. Renal Safety of Tenofovir Disoproxil Fumarate in HIV-1 Treatment- Experienced Patients With Adverse Events Related to Prior NRTI Use: Data From a Prospective, Observational, Multicenter Study.

Author

Moreno, Santiago, Domingo, Pere, Palacios, Rosario, Santos, Jesus, Falcé, Vicenç, Murillas, Javier, Estrada, Vicente, Ena, Javier, and Alvarez, Maria Luisa

Subjects
*LETTERS to the editor, *HIV infections
Abstract

A letter to the editor is presented concerning tenofovir disoproxil fumarate, the sole nucleotide analogue reverse transcriptase inhibitor that is approved for the treatment of HIV-1 infection.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results